Cite
HARVARD Citation
Morschhauser, F. et al. (2022). Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. Journal of clinical oncology. 40 (28), pp. 3239-3245. [Online].